Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK2206 every other day · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| QOD Schedule | EXPERIMENTAL | QOD Schedule, MK2206 every other day |
| QW Schedule | EXPERIMENTAL | QW Schedule, MK2206 once weekly |
| Name | Type | Description |
|---|---|---|
| MK2206 every other day | DRUG | Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 45 mg and 60 mg, once daily every other day in repeating 4 week cycles. |
| MK2206 once weekly | DRUG | Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 135 mg and 200 mg, once weekly in repeating 4 week cycles. |
Inclusion Criteria: * Patient must have confirmed locally advanced or metastatic solid tumors that have failed to respond to standard therapy, have gotten worse or have come back after existing therapy * Has adequate organ function * Is ECOG Performance Scale 0-1 * Has a negative urine pregnancy te...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MK2206 every other day is an investigational small molecule being studied for the treatment of solid tumors, specifically locally advanced or metastatic solid tumors. It is an oral drug administered every other day and is currently in Phase 1 clinical development.
MK2206 every other day is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is an investigational small molecule in Phase 1 clinical development for solid tumors.
MK2206 every other day is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities, and is being studied for the treatment of solid tumors. One Phase 1 trial has been completed.
MK2206 every other day has one completed clinical trial, NCT01071018, titled "A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)." This Phase 1 trial enrolled 24 participants with solid tumors and was a controlled, open-label study.
MK2206 every other day is a dosing schedule of the drug MK2206, where the medication is administered every other day rather than daily. The clinical trial NCT01071018 specifically evaluated this every-other-day regimen in patients with solid tumors.